Mid-cap Health Care company Exact Sciences has logged a 1.6% change today on a trading volume of 1,780,704. The average volume for the stock is 3,220,845.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. Based in Madison, United States the company has 6,900 full time employees and a market cap of $8,670,810,112.
The company is now trading -27.27% away from its average analyst target price of $62.97 per share. The 23 analysts following the stock have set target prices ranging from $46.0 to $80.0, and on average give Exact Sciences a rating of buy.
Over the last 12 months EXAS shares have declined by -23.3%, which represents a difference of -38.6% when compared to the S&P 500. The stock's 52 week high is $72.83 per share and its 52 week low is $38.81. With its net margins declining an average -7.6% over the last 6 years, Exact Sciences declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 2,758,867 | -1,028,857 | -37 | -362.5 |
| 2023 | 2,499,766 | -204,149 | -8 | 73.33 |
| 2022 | 2,084,279 | -623,506 | -30 | 11.76 |
| 2021 | 1,767,087 | -595,625 | -34 | 38.18 |
| 2020 | 1,491,391 | -823,605 | -55 | -129.17 |
| 2019 | 876,293 | -213,090 | -24 |
